BioSpace News Archive

bluebird, Celgene Tout ‘Unheard of’ Early-Stage Multiple Myeloma Data

Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.

December 10, 2017

·

2 min read

·

Mark Terry

Drug Development

Genentech’s Hemlibra Data Continues to Wow at ASH

One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.

December 10, 2017

·

4 min read

·

Alex Keown

Gemini Therapeutics Banks $42.5M to Bring Precisio

Drug Development

Syros Crushed as Lead Drug is Failing Its Phase II Trial Badly

Investors are not happy with interim Phase II data presented by Syros.

December 10, 2017

·

2 min read

·

Alex Keown

Drug Development

Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

The new data from the dose escalation portion of the Phase I trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.

December 10, 2017

·

15 min read

Drug Development

ASH Release: Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies

Four studies being presented today at the 59th ASH Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

December 10, 2017

·

15 min read

Genetown

Takeda and Seattle Genetics to Present Positive Data from Phase III ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017.

December 10, 2017

·

29 min read

Seattle Genetics Highlights Five-Year Survival Results from Phase I Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting

The presentation highlighted durability data from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of patients with newly diagnosed MTCL, also known as peripheral T-cell lymphoma (PTCL).

December 10, 2017

·

15 min read

Drug Development

ASH Release: CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

Among 108 patients with fast-growing and refractory aggressive NHL, more than half were still alive at least a year after receiving a single infusion of a CAR T-cell therapy, axi-cel, that targets the CD-19 protein frequently found on cancerous lymphoma cells, researchers reported.

December 10, 2017

·

12 min read

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

December 10, 2017

·

13 min read

Drug Development

bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

bluebird bio announced data from two studies of its LentiGlobin gene therapy product candidate in patients with transfusion-dependent β-thalassemia (TDT).

December 10, 2017

·

10 min read